Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide in AML/MDS with Low MGMT Expression
NCT00687323Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2007
- Primary completion
- May 2011
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of temozolomide in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Merck & Co.. Started Jul 2007; status: completed.
02
Drugs
temozolomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00687323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687323.